ArticleClinical journal of gastroenterology2026
Cytomegalovirus gastritis following immune checkpoint inhibitor-associated gastritis induced by ipilimumab and nivolumab therapy in a patient with renal cell carcinoma.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of advanced malignancies. By enhancing antitumor immunity through T-cell modulation, ICIs can induce immune-related adverse events (irAEs) resulting from aberrant T-cell activation. We report the case of a 69-year-old woman with renal cell carcinoma and lung metastases who received combination therapy with ipilimumab and nivolumab. After the fifth cycle, she developed anorexia and epigastric pain. Abdominal computed tomography revealed marked thickening of the gastric wall from the antrum to the pylorus, and upper gastrointestinal endoscopy showed erosions with a white coating and thickened gastric folds. Histological examination of a gastric biopsy revealed infiltration of inflammatory cells, and immunohistochemistry demonstrated prominent infiltration of CD8-positive lymphocytes, leading to a diagnosis of irAE gastritis. Treatment with prednisolone was initiated, resulting in improvement of both symptoms and endoscopic findings. However, gastric erosions recurred during tapering of prednisolone. A repeat biopsy showed a reduction in CD8-positive cells but revealed an increase in cytomegalovirus (CMV)-positive cells. Furthermore, serum CMV antigenemia, which was negative before steroid treatment, became positive, supporting the diagnosis of CMV gastritis. Valganciclovir was initiated, and prednisolone was discontinued. Treatment with valganciclovir led to ulcer healing and resolution of CMV antigenemia. Although irAE gastritis is a rare complication of ICI therapy, it should be considered in patients presenting with upper gastrointestinal symptoms during treatment. The management of irAE gastritis requires vigilance for opportunistic infections, timely histopathological evaluation, and careful differentiation from viral infections, especially in cases refractory to corticosteroids.
Indexed as
Identifiers
41670782What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.